Skip to content

Exploration of modified IPACK in perioperative analgesia for total knee arthroplasty

Exploration of modified IPACK in perioperative analgesia for total knee arthroplasty

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093887
Enrollment
Unknown
Registered
2024-12-13
Start date
2024-12-16
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Experimental group:rIPACK block

Sponsors

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 80 years old; 2. ASA (American Society of Anesthesiologists) physical status classification I-III; 3. Undergoing elective unilateral knee replacement surgery under general anesthesia; 4. BMI (Body Mass Index) between 18.5 and 30 kg/m² [BMI = weight (kg) / height (m)²]; 5. Ethically compliant, with voluntary participation and signed informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1. History of undergoing surgery under general anesthesia within the past month; 2. Preexisting severe systemic diseases of the heart, lungs, or brain, such as hypertension, coronary artery disease, COPD, asthma, respiratory failure, pulmonary hypertension, severe arrhythmias (atrial fibrillation, second-degree or higher atrioventricular block, sick sinus syndrome, etc.), severe heart valve disease, heart failure, renal failure, stroke or myocardial infarction within the past 6 months, Alzheimer's disease, Parkinson's disease, psychiatric disorders, OSAS (Obstructive Sleep Apnea Syndrome), myasthenia gravis, etc.; 3. History of chronic pain in other parts of the body; 4. Patients with liver or kidney dysfunction; 5. Patients with a history of allergy to medications used in this study; 6. History of opioid abuse or use of opioids within the past two weeks; 7. Abnormal coagulation function; 8. METs (Metabolic Equivalents) < 4; 9. Patients who refuse or are unable to cooperate with participation in this study; 10. Participation in other studies within the past 30 days.

Design outcomes

Primary

MeasureTime frame
Intraoperative sufentanil dosage;

Secondary

MeasureTime frame
Resting NRS score;Passive knee flexion NRS (Numerical Rating Scale) score;Ambulation NRS score;Knee extension strength;Hip flexion strength;Dorsiflexion strength;Plantarflexion strength;Hemodynamic parameters;IoC (Index of Consciousness);Postoperative hydromorphone dosage and PCA (Patient-Controlled Analgesia) usage;Cardiovascular agent dosage;surgical duration;tourniquet time;Ambulation time;length of stay (LOS);

Countries

China

Contacts

Public ContactTao Xu

Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

balor@sjtu.edu.cn+86 189 3017 3660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026